Membership Level

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,000+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market an internally-discovered product, BRUKINSA® (zanubrutinib) in the United States. To learn more about BeiGene, visit and follow us on Twitter at @BeiGeneUSA.

BeiGene: Blood Cancer Has No Borders, Neither Do We:

More information:

Click the link to view BeiGene’s activities and presentations presented this year during the 25th European Hematology Association (EHA) Virtual Congress that took place on June 11-14.

© 2021 FLASCO | Premium Website Design by The HDG